According to FutureWise analysis the market for musculoskeletal oncology therapeutics in 2023 is US$ 1.88 billion, and is expected to reach US$ 2.73 billion by 2031 at a CAGR of 4.72%.
Musculoskeletal oncology, also known as orthopedic oncology, is a highly specialised branch of orthopedic surgery. Musculoskeletal oncology treats sculoskeletal cancers and tumours. Bone and soft tissue tumors are quite rare and can require reconstructive surgery. Sarcomas of soft tissue are more common than those of bone. The American Cancer Society estimates about 3,300 new cases of cancer of the bones and joints in 2016 and 12,310 new cases of soft tissue sarcomas.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Musculoskeletal Oncology Therapeutics Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Musculoskeletal Oncology Therapeutics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.